Methods, products and treatments for diabetes
The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.
1. A method for identifying a subject at risk for a disorder associated with diabetes, said disorder being characterized by abnormally high levels of glycated CD59 protein, comprising;
obtaining a level of the amount of K41-glycated CD59 from a sample obtained from the subject, and
comparing the level of K41-glycated CD59 in the sample to a control level as a determination of the subject's risk for a disorder associated with diabetes, said disorder being characterized by abnormally high levels of glycated CD59 protein.
2. The method of claim 1 , wherein the sample is a fluid sample.
3. The method of claim 2 , wherein the fluid sample is blood.
4. The method of claim 2 , wherein the fluid sample is urine.
5. The method of claim 2 , wherein the fluid sample is saliva.
6. The method of claim 1 , wherein the sample is a tissue sample.
7. The method of claim 1 , wherein the subject is diabetic.
8. The method of claim 1 , wherein the subject has a diabetic condition.
9. The method of claim 1 , wherein the diabetic condition is an abnormal blood sugar level.
10. The method of claim 1 , wherein the subject is at increased risk of having a diabetic condition.
11. The method of claim 1 , wherein the control level is the level in apparently healthy normal individuals.
12. The method of claim 1 , wherein the control level is a predetermined value.
13. The method of claim 1 , wherein the control level is a level determined for the subject from a second sample obtained from the subject at a separate time.
14. The method of claim 1 , wherein the level is measured as a percentage of the total CD59 in the sample.
15. The method of claim 1 , wherein the level is the level of K41-glycated CD59 relative to the level of nonglycated CD59 in the sample.
16. The method of claim 15 , wherein the nonglycated CD59 is non K41-glycated CD59.
17. The method of claim 1 , wherein the sample is a blood, saliva, or urine sample and the control level is the level of K41-glycated CD59 in a non-diabetic condition.
18. The method of claim 1 , wherein, the sample is a blood, saliva, or urine sample, and the control level is the level of K41-glycated CD59 in a second blood, saliva, or urine sample obtained from the subject at a seperate time.
19. The method of claim 1 , wherein the subject is at risk for a vascular complication.
20. An isolated composition comprising K41-glycated CD59.